BioWorld

June 18, 2003

MedImmune's Intranasal Vaccine FluMist Receives FDA Approval

MedImmune Inc. received long-awaited news late Tuesday afternoon as the FDA approved FluMist, a nasally delivered product that has ridden a rocky road throughout the regulatory review process. (BioWorld Today) Read More

Cell Therapeutics, Novuspharma Merging In $236M Stock Exchange

Alcohol Abuse In Pregnancy Can Bring On Fetal Alcohol Syndrome, Mental Retardation In The Young

Biomira, Merck KGaA Report Failed Theratope Phase III Trial

BioMarin Aiming To Raise $125M In Convertible Notes

Questcor Raises $5M To Fund $18.2M Purchase Of Nascobal

Boston Life Sciences Plans Another Altropane Phase III

Amylin Sends Symlin Amendment To FDA, Seeks $150M In Notes

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 16, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Celia trial: data strong, analysts skeptical

BioWorld

Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Illustration of T cells attacking cancer

GABA signaling linked to immune resistance in some tumors

BioWorld

Certain cancers that contain organized clusters of immune cells known as tertiary lymphoid structures (TLS) do not respond to treatment as well as expected. Even...